Personalized Medicine in Cancer Pain Management
Journal of Personalized Medicine · 28.07.2023 · 13 (8) · 1201
DOI: 10.3390/jpm13081201 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 28.07.2023. Verfasst von Mohammad Raad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824, USA. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schmerzmanagement
Abstract (Originalsprache)
Background
Previous studies have documented pain as an important concern for quality of life (QoL) and one of the most challenging manifestations for cancer patients. Thus, cancer pain management (CPM) plays a key role in treating pain related to cancer. The aim of this systematic review was to investigate CPM, with an emphasis on personalized medicine, and introduce new pharmacogenomics-based procedures for detecting and treating cancer pain patients.
Methods
This study systematically reviewed PubMed from 1990 to 2023 using keywords such as cancer, pain, and personalized medicine. A total of 597 publications were found, and after multiple filtering processes, 75 papers were included. In silico analyses were performed using the GeneCards, STRING-MODEL, miRTargetLink2, and PharmGKB databases.
Results
The results reveal that recent reports have mainly focused on personalized medicine strategies for CPM, and pharmacogenomics-based data are rapidly being introduced. The literature review of the 75 highly relevant publications, combined with the bioinformatics results, identified a list of 57 evidence-based genes as the primary gene list for further personalized medicine approaches. The most frequently mentioned genes were CYP2D6, COMT, and OPRM1. Moreover, among the 127 variants identified through both the literature review and data mining in the PharmGKB database, 21 variants remain as potential candidates for whole-exome sequencing (WES) analysis. Interestingly, hsa-miR-34a-5p and hsa-miR-146a-5p were suggested as putative circulating biomarkers for cancer pain prognosis and diagnosis.
Conclusions
In conclusion, this study highlights personalized medicine as the most promising strategy in CPM, utilizing pharmacogenomics-based approaches to alleviate cancer pain.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824, USA.
- Neurosurgeon Clinica Foscal Internacional, Bucaramanga 680006, Colombia.
- Neurosurgeon Clinica Portoazul, Caribe, La Merced, Asunción, Centro, Barranquilla 680006, Colombia.
- Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht 41937-1311, Iran.
- University of North Carolina, Greensboro, NC 27412, USA.
- Center for Advanced Spine Care of Southern Arizona, Tucson, AZ 85712, USA.
ORCID-Profile: Mohammad Raad, Alireza Sharafshah, Kai-Uwe Lewandrowski
Zitieren
APA
Raad, M., López, W. O. C., Sharafshah, A., Assefi, M., & Lewandrowski, K. U. (2023). Personalized Medicine in Cancer Pain Management. Journal of Personalized Medicine, 13(8), 1201. https://doi.org/10.3390/jpm13081201
Vancouver
Raad M, López WOC, Sharafshah A, Assefi M, Lewandrowski KU. Personalized Medicine in Cancer Pain Management. Journal of Personalized Medicine. 2023;13(8):1201. doi:10.3390/jpm13081201
BibTeX
@article{Raad2023,
author = {Raad, Mohammad and López, William Omar Contreras and Sharafshah, Alireza and Assefi, Marjan and Lewandrowski, Kai-Uwe},
title = {Personalized Medicine in Cancer Pain Management},
journal = {Journal of Personalized Medicine},
year = {2023},
volume = {13},
number = {8},
pages = {1201},
doi = {10.3390/jpm13081201}
}
EUVIMED